Compare Jabil Inc (JBL) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jabil Inc vs ResMed Inc. — how do they compare? Jabil Inc trades at $305.62 (market cap $31.35B), while ResMed Inc. trades at $230.12 (market cap $31.89B). The key difference: Jabil Inc and ResMed Inc. are close in size by market cap, and ResMed Inc. pays the higher dividend (1.16%). Which is the better fit depends on your goals — on Pluang, investors hold Jabil Inc for 23 Days and ResMed Inc. for 51 Days on average.
| JBL | RMD | |
|---|---|---|
Market Cap | $31.35B | $31.89B |
Volume | 1,337,978 | 618,314 |
Sector | Technology | Health |
52-Week High | $385.50 | $277.88 |
52-Week Low | $192.49 | $182.82 |
Typical Hold Time | 23 Days | 51 Days |
Enterprise Value | $33.63B | $31.24B |
Dividend Yield | 0.11% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBL trades at $305.83, up 2.12% with strong Q4 2026 earnings beating estimates at $4.40 EPS versus $4.07 expected. Technical indicators show bearish signals with price near resistance at $304, while fundamentals reveal robust revenue growth to $36.0B projected for 2026 and a high ROE of 74.11%. Recent news highlights AI infrastructure demand driving fiscal 2027 growth targets of 24%.
The outlook is positive with analyst consensus price target of $434.75 implying 42% upside, supported by 14 buy ratings and no sells. Risks include high debt levels and market volatility despite strong earnings, but AI-driven expansion and consistent earnings beats present a compelling growth opportunity for investors.
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
